Evidence map›Paper›PMID 26818459›Full record

ReviewNutrition journal2016

Oral hyaluronan relieves knee pain: a review.

Mariko Oe, Toshiyuki Tashiro, Hideto Yoshida, Hiroshi Nishiyama, Yasunobu Masuda, Koh Maruyama, Takashi Koikeda, Reiko Maruya, Naoshi Fukui

2 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in Nutrition journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03421054 nacompletednot on this mapstarted 2018, after this paper: background citation

Pilot, Open Non-controled Trial to Assess the Feasibility of Implementing Objective Parameters as Primary Endpoints in a Clinical Trial With Patients Affected by Knee Osteoarthritis

TypeinterventionalSponsorRiver Pharma S.r.l.Ran2018 to 2018Enrolled8ConditionsKnee OsteoarthritisArmspatients assuming nutraceutical containing HA
NCT03612986 nacompletednot on this mapstarted 2018, after this paper: background citation

Double Blind, Placebo Controlled Trial to Evaluate the Effects of a Nutraceutical Containing High-Molecular-Weight Hyaluronic Acid (HA) and Acetyl-11-Keto-Beta-Boswellic Acid (AKBA) in Patients Affected by Knee Osteoarthritis

TypeinterventionalSponsorRiver Pharma S.r.l.Ran2018 to 2019Enrolled72ConditionsKnee OsteoarthritisArmsSYALOX® 300 Plus, Placebo
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Polymers · 2023
    Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 3 countries.

Mariko OeR&D Division, Kewpie Corporation, 2-5-7, Sengawa-cho, Chofu-shi, Tokyo, Japan. mariko_oe@kewpie.co.jp.
Toshiyuki TashiroTokyo Yamate Medical Center, 3-22-1 Hyakunin-cho, Shinjyuku-ku, Tokyo, Japan. tsyktashiro@yahoo.co.jp.
Hideto YoshidaR&D Division, Kewpie Corporation, 2-5-7, Sengawa-cho, Chofu-shi, Tokyo, Japan. hideto_yoshida@kewpie.co.jp.
Hiroshi NishiyamaR&D Division, Kewpie Corporation, 2-5-7, Sengawa-cho, Chofu-shi, Tokyo, Japan. hiroshi_nishiyama@kewpie.co.jp.
Yasunobu MasudaR&D Division, Kewpie Corporation, 2-5-7, Sengawa-cho, Chofu-shi, Tokyo, Japan. yasunobu_masuda@kewpie.co.jp.
Koh MaruyamaGate Town Hospital, 1-6-19, Sekimachi-kita, Nerima-ku, Tokyo, Japan. gthsplab@sweet.ocn.ne.jp.
Takashi KoikedaShiba Palace Clinic, 1-9-10 Hamamatsucho, Minato-ku, Tokyo, Japan. shiba_palace@s-palace-clinic.com.
Reiko MaruyaSOUKEN Corporation, 1-9-10, Hamamatsu-cho, Minato-ku, Tokyo, Japan. maruya@souken-lab.co.jp.
Naoshi FukuiDepartment of Life Science, Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1 Komaba, Meguro-ku, Tokyo, Japan. n-fukui@idaten.c.u-tokyo.ac.jp.
Keihin (Japan) · JPBruker (United States) · USNerima General Hospital · JPPalace Museum · CNSeiko Holdings (Japan) · JPThe University of Tokyo · JPTokyo Yamate Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyaluronan (HA) is a component that is particularly abundant in the synovial fluid. Randomized, double-blinded, placebo-controlled trials carried out between 2008 and 2015 have proven the effectiveness of HA for the treatment of symptoms associated with synovitis, and particularly, knee pain, relief of synovial effusion or inflammation, and improvement of muscular knee strength. The mechanism by which HA exerts its effects in the living body, specifically receptor binding in the intestinal epithelia, has gradually been clarified. This review examines the effects of HA upon knee pain as assessed in clinical trials, as well as the mechanism of these effects and the safety of HA.

Indexed as

Administration, OralHumansHyaluronic AcidOsteoarthritis, KneePainQuality of LifeRandomized Controlled Trials as TopicHyaluronic Acid

Identifiers

PMID26818459
PMCPMC4729158
OpenAlexW2266618386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.